624 related articles for article (PubMed ID: 17015493)
1. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.
Maegawa GH; Stockley T; Tropak M; Banwell B; Blaser S; Kok F; Giugliani R; Mahuran D; Clarke JT
Pediatrics; 2006 Nov; 118(5):e1550-62. PubMed ID: 17015493
[TBL] [Abstract][Full Text] [Related]
2. Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.
Lyn N; Pulikottil-Jacob R; Rochmann C; Krupnick R; Gwaltney C; Stephens N; Kissell J; Cox GF; Fischer T; Hamed A
Orphanet J Rare Dis; 2020 Apr; 15(1):92. PubMed ID: 32295606
[TBL] [Abstract][Full Text] [Related]
3. GM2 gangliosidosis variant B1 neuroradiological findings.
Grosso S; Farnetani MA; Berardi R; Margollicci M; Galluzzi P; Vivarelli R; Morgese G; Ballestri P
J Neurol; 2003 Jan; 250(1):17-21. PubMed ID: 12527987
[TBL] [Abstract][Full Text] [Related]
4. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.
Nestrasil I; Ahmed A; Utz JM; Rudser K; Whitley CB; Jarnes-Utz JR
Mol Genet Metab; 2018 Feb; 123(2):97-104. PubMed ID: 29352662
[TBL] [Abstract][Full Text] [Related]
5. Clinical, Imaging, Genetic, and Disease Course Characteristics in Patients With GM2 Gangliosidosis: Beyond Age of Onset.
Kern J; Böhringer J; Timmann D; Trollmann R; Stendel C; Kamm C; Röbl M; Santhanakumaran V; Groeschel S; Beck-Wödl S; Göricke S; Krägeloh-Mann I; Synofzik M
Neurology; 2024 Jan; 102(1):e207898. PubMed ID: 38165373
[TBL] [Abstract][Full Text] [Related]
6. Plasma G
Blondel A; Kraoua I; Marcelino C; Khrouf W; Schlemmer D; Ganne B; Caillaud C; Fernández-Eulate G; Turki IBY; Dauriat B; Bonnefont-Rousselot D; Nadjar Y; Lamari F
Mol Genet Metab; 2023 Feb; 138(2):106983. PubMed ID: 36709536
[TBL] [Abstract][Full Text] [Related]
7. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients.
Neudorfer O; Pastores GM; Zeng BJ; Gianutsos J; Zaroff CM; Kolodny EH
Genet Med; 2005 Feb; 7(2):119-23. PubMed ID: 15714079
[TBL] [Abstract][Full Text] [Related]
8. GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed.
Smith NJ; Winstone AM; Stellitano L; Cox TM; Verity CM
Dev Med Child Neurol; 2012 Feb; 54(2):176-82. PubMed ID: 22115551
[TBL] [Abstract][Full Text] [Related]
9. Diagnosing Lysosomal Storage Disorders: The GM2 Gangliosidoses.
Hall P; Minnich S; Teigen C; Raymond K
Curr Protoc Hum Genet; 2014 Oct; 83():17.16.1-8. PubMed ID: 25271840
[TBL] [Abstract][Full Text] [Related]
10. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
Gort L; de Olano N; Macías-Vidal J; Coll MA;
Gene; 2012 Sep; 506(1):25-30. PubMed ID: 22789865
[TBL] [Abstract][Full Text] [Related]
11. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
12. Natural History of Adult Patients with GM2 Gangliosidosis.
Masingue M; Dufour L; Lenglet T; Saleille L; Goizet C; Ayrignac X; Ory-Magne F; Barth M; Lamari F; Mandia D; Caillaud C; Nadjar Y
Ann Neurol; 2020 Apr; 87(4):609-617. PubMed ID: 31995250
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
[TBL] [Abstract][Full Text] [Related]
14. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants).
Clarke JT; Mahuran DJ; Sathe S; Kolodny EH; Rigat BA; Raiman JA; Tropak MB
Mol Genet Metab; 2011 Jan; 102(1):6-12. PubMed ID: 20926324
[TBL] [Abstract][Full Text] [Related]
15. GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.
Demir SA; Timur ZK; Ateş N; Martínez LA; Seyrantepe V
J Neuroinflammation; 2020 Sep; 17(1):277. PubMed ID: 32951593
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and molecular aspects of late-onset GM2-gangliosidosis: B1 variant as a prototype.
Suzuki K; Vanier MT
Dev Neurosci; 1991; 13(4-5):288-94. PubMed ID: 1840099
[TBL] [Abstract][Full Text] [Related]
17. [Tay-Sachs disease].
Tanaka A
Nihon Rinsho; 1993 Sep; 51(9):2281-5. PubMed ID: 8411703
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and molecular characterization of non-classic forms of Tay-Sachs disease in Brazil.
Rozenberg R; Kok F; Burin MG; Sá Miranda MC; Vasques C; Henriques-Souza AM; Giugliani R; Vainzof M; Pereira LV
J Child Neurol; 2006 Jun; 21(6):540-4. PubMed ID: 16948947
[TBL] [Abstract][Full Text] [Related]
19. Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system.
Miklyaeva EI; Dong W; Bureau A; Fattahie R; Xu Y; Su M; Fick GH; Huang JQ; Igdoura S; Hanai N; Gravel RA
Brain Res; 2004 Mar; 1001(1-2):37-50. PubMed ID: 14972652
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
